The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...
GlobalData on MSN18h
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEODaiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
Abridge, the leading AI platform for clinical conversations, has appointed Sagar Sanghvi as its first Chief Financial Officer for its next phase of growth. With nearly fifteen years of experience as ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback